U.S. House Speaker Touts Benefits Of CBD And Industrial Hemp

The top Republican in the U.S. House has issued a surprise endorsement of a key marijuana ingredient’s medical benefits, as well as the uses of industrial hemp.

“It has proven to work,” Republican House Speaker Paul Ryan said of cannabidiol (CBD) on Oct. 30, 2018, specifying that it “helps reduce seizures.”

“We do this in Wisconsin,” he said, referring to his home state’s limited CBD law. “That that oil, I think works well.”

The speaker, who is not running for re-election and is retiring from Congress early next year, shared that his own mother-in-law used a synthetic form of cannabinoids, presumably the tetrahydrocannabinol (THC) pill Marinol, while dying from melanoma and ovarian cancer.

“That’s off the record,” he said jokingly, referencing TV cameras at the well-attended Kentucky rally where he was appearing in support of Republican Rep. Andy Barr, who is locked in a tight re-election race.

Ryan, responding to a medical marijuana question from a woman whose husband died, also proactively took the opportunity to speak up in support of industrial hemp.

“And by the way, there’s a lot of industrial uses for hemp that I understand from talking to Mitch McConnell is a big deal to Kentucky agriculture,” he said. “And we’re all in favor of that as well.”

Ryan’s endorsement for hemp comes at a key time. Congressional leaders are currently negotiating differences in the House and Senate versions of the Farm Bill. The Senate proposal contains language championed by McConnell, the GOP majority leader, that would legalize hemp. The House bill has no such provisions.

If the top Republican in either chamber is now vocally in support of ending the prohibition on marijuana’s non-intoxicating cousin, it seems more and more likely that the House will accept the Senate’s hemp language.

That said, don’t count the outgoing speaker as a die-hard marijuana supporter, even when it comes to medical uses.

“There’s no THC in that oil,” he said, even though most CBD preparations do have small amounts of the intoxicating cannabis compound. “That is not medical marijuana.”

In response to the medical marijuana question, Ryan also touted passage this year of the Right to Try Act — which appears to allow certain seriously ill people to use marijuana and other currently illegal drugs such as psilocybin, or “magic mushrooms,” and MDMA, popularly called ecstasy, though he did not mention those implications directly.

This article has been republished from Marijuana Moment under a content syndication agreement. Read the original article here.

Original Article Source: https://www.marijuana.com/news/2018/10/u-s-house-speaker-touts-benefits-of-cbd-and-industrial-hemp/

Comments

Could CBD Lead To The Development Of Safer Antipsychotic Medications?

Antipsychotic medications are important for managing a number of different psychiatric ailments, including bipolar disorders, schizophrenia, and even dementia. These drugs can greatly improve the manageability of symptoms that often distort one’s experience of reality. They can also create major mood disruptions and lead to a number of behavioral and emotional difficulties. Antipsychotic and anti-psychosis medications can be life-changing for people with such disorders, enabling them to live more normal and manageable lives without their symptoms taking over. These drugs work by regulating neurotransmitters in the brain so that naturally occurring imbalances and dysfunctions no longer disrupt mental and emotional processes. Often, reaching this outcome is much easier said than done; it can take a lot of time to find courses and combinations of treatments that work. It’s sometimes necessary to make adjustments to find the right balance for the individual and it’s not unusual for outc...

Cannabis Watch: Canopy Growth To Book Charge Of Up To $568 Million As Marijuana Restructuring Continues

Canopy Growth Corp. said early Thursday it was halting a range of operations across three continents and expects its restructuring plans to result in a charge of up to C$800 million (567.9 million) in the fiscal fourth quarter. U.S.-traded shares US:CGC CA:WEED of the cannabis company fell 1.9% in afternoon trading. Canopy said it was selling operations in Africa, curtailing cultivation of hemp in the U.S. and Columbia, and shutting down an indoor production facility in Canada. The announcement will result in 85 job cuts, the company said. “When I arrived at Canopy Growth in January, I committed to conducting a strategic review in order to lower our cost structure and reduce our cash burn,” Canopy Chief Executive David Klein said in a statement. Read: As cannabis industry stays largely quiet on coronavirus, this CEO has been sounding the alarm Canopy’s restructuring announcement was expected by investors, Cowen analyst Vivien Azer wrote in a note to clients Thursday. Azer rate...

Can Medical Marijuana Help Aging Parents With Dementia?

For decades, marijuana, even for medical uses, was demonized or questioned. When states like Colorado legalized it for recreational use, more studies began to determine provable efficacy for its use as a medicine. The Federal government still classifies marijuana the same way it classifies heroin: harmful and with no medical benefits. Now we can see that this is wrong. When states legalized marijuana, referred to as cannabis here, they had an interest in getting data to see what good it could do. Proving efficacy could increase medical marijuana sales, benefit people who might at least find some medical use, and overall would bring tax dollars into the state coffers. Without funding studies, the Federal government has done very little to demonstrate what good cannabis can do. After all, if the presumption is that it helps nothing, there would be no motivation to determine with scientific data that it does anyone any good. But we have convincing data now about its beneficial use ...

Norma Pence

Search This Blog